In pharmacological treatments for glaucoma, the primary mechanisms for lowering IOP include inhibiting aqueous humor secretion or facilitating aqueous humor drainage. Carbonic anhydrase inhibitors (CAIs) are among the oldest IOP-lowering drugs, reducing aqueous humor production by inhibiting the interconversion of carbon dioxide and bicarbonate in the ciliary body. However, topical drug treatments can be complicated by poor patient compliance, low bioavailability, and side effects. Given that glaucoma requires lifelong management as a chronic disease, daily medication and combination therapy with multiple drugs are common in clinical practice. Thus, developing a convenient, effective, and durable treatment method is urgently needed for the long-term management of glaucoma patients. Due to the eye’s accessible nature and immune-privileged characteristics, gene therapy is considered a promising new approach for glaucoma treatment.
On April 25, 2024, the team of Xiulan Zhang from the Zhongshan Ophthalmic Center at Sun Yat-sen University, and the team of Patrick Yu Wai Man from the University of Cambridge jointly published a research paper titled “CRISPR-Cas9-mediated deletion of carbonic anhydrase 2 in the ciliary body to treat glaucoma” in “Cell Reports Medicine” (IF 14.3). Dr. Jiaxuan Jiang and Dr. Kangjie Kong are the co-first authors of this paper. The study used the AAV ShH10 to deliver the CRISPR-Cas9 system, precisely targeting the Car2 gene in the ciliary body. This approach effectively reduced IOP in an experimental glaucoma mouse model and provided long-term mitigation or even prevention of glaucoma damage caused by sustained high IOP, offering a potential new treatment strategy for glaucoma patients.
*PackGene Contributed the vector construction and AAV packaging services for this research
In Vitro Experiments
- Plasmid Vectors: ssAAV.U6.(Sp)sgRNA.CAG.SV40 NLS-EGFP.WPRE, ssAAV.miniCMV.SpCas9
- Promoters: U6, miniCMV, CAG
- Cell Type: Neuro-2a (N2a) cells
- Transfection Method: Lipofectamine 3000 transfection
- Detection Methods: Sanger sequencing, T7E1 assay, GUIDE-seq
In Vivo Experiments
- Viral Vectors: AAV shH10-SpCas9, AAV shH10-sgRNA
- Promoters: U6, miniCMV, CAG
- Injection Sites: DBA/2J mice, intravitreal injection
- Injection Dose: 1 x 10^13 gc/mL, 2μL
- Detection Time: 1 week post-injection
- Detection Methods: Immunofluorescence imaging, Capillary-based immunoassay, qPCR, etc.
Check out our AAV CDMO service to expedite your gene therapy research
1. DOI: https://doi.org/10.1016/S0140-6736(17)31469-1
2. DOI: https://doi.org/10.1016/j.xcrm.2024.101524
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
More Articles
Novel Approach in T Cell Engineering: Lipid Nanoparticles Enable Advanced Genome Editing for Cancer Therapies
Revolutionizing CAR T Cell Therapy with Lipid Nanoparticles Chimeric antigen receptor (CAR) T cell therapy has transformed cancer treatment by turning a patient’s own T cells into powerful cancer-fighting agents. However, as the technology advances, there is an...
New Lipid Nanoparticles Deliver CRISPR-Cas9 to Knock Down Angptl3 in Mice
A team of researchers has developed a new way to deliver CRISPR-Cas9 genome editing tools directly to the liver, targeting a gene called Angptl3 that’s linked to high cholesterol and triglyceride levels. This breakthrough could pave the way for new treatments for...
Ex Vivo Gene Correction of Stem Leydig Cells as a Therapeutic Strategy for Hereditary Primary Hypogonadism
Leydig cells (LCs), located in the interstitial compartment of the testes among the seminiferous tubules, are primarily responsible for testosterone production, which is crucial for maintaining the masculine phenotype, endocrine homeostasis, and reproductive function....
Enhancing Diabetic Wound Healing Through Local Silencing of PHD2 and Activation of the AMPK Pathway
Recent data from the International Diabetes Federation (IDF) indicates that in 2017, approximately 425 million people globally were diagnosed with diabetes, with China accounting for 114 million of these cases, the highest number worldwide. One of the main...
Related Services
AAV Packaging Services
READ MORE
AAV Packaging Service (NHP)
READ MORE
AAV Packaging Service (HT)
READ MORE